

**Question for written answer E-001843/2023  
to the Commission**

Rule 138

**Christine Anderson (ID)**

Subject: Commission acquisition strategy for vaccine doses – 5

I would like to refer to the previous questions P-000579/22<sup>1</sup>, P-001357/22<sup>2</sup>, E-003434/22<sup>3</sup> and E-003435/22<sup>4</sup>. The Commission had signed contracts for a total of 4.6 billion vaccine doses. Now, the Commission is negotiating the cancellation of these orders<sup>5</sup>.

1. What quantities of vaccines were ordered from which manufacturers and when?
2. How were these 4.6 billion doses initially meant to be distributed between the individual Member States, and how many vaccine doses has each Member State actually taken up so far?
3. To what extent does the Commission need to financially compensate the manufacturers for vaccine doses that it does not take up, and how is this financial compensation distributed between individual Member States?

Submitted: 8.6.2023

---

<sup>1</sup> [https://www.europarl.europa.eu/doceo/document/P-9-2022-000579\\_EN.html](https://www.europarl.europa.eu/doceo/document/P-9-2022-000579_EN.html)

<sup>2</sup> [https://www.europarl.europa.eu/doceo/document/P-9-2022-001357\\_EN.html](https://www.europarl.europa.eu/doceo/document/P-9-2022-001357_EN.html)

<sup>3</sup> [https://www.europarl.europa.eu/doceo/document/E-9-2022-003434\\_EN.html](https://www.europarl.europa.eu/doceo/document/E-9-2022-003434_EN.html)

<sup>4</sup> [https://www.europarl.europa.eu/doceo/document/E-9-2022-003435\\_EN.html](https://www.europarl.europa.eu/doceo/document/E-9-2022-003435_EN.html)

<sup>5</sup> <https://www.euractiv.de/section/europa-kompakt/news/geringe-nachfrage-kommission-verhandelt-impfstoffvertraege-neu/>